GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.
"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment."
The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results adminPage: 1 2 3 4 Related medicine news :1
. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting2
. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function3
. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease4
. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue5
. Gastrointestinal disorders are associated significantly with sleepless nights6
. Landmark survey reveals asthma in children remains significantly out of control in the United States7
. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD8
. Elderly cancer patients are significantly under-represented in cancer clinical trials9
. Generic anti-inflammatory causes significantly fewer GI complications than branded medications10
. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...11
. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer